Atsuo Tahara

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 310 citations

Medicine, Endocrinology, Pharmacology +17

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 194 citations · Full text

Life Sciences, Endocrinology, Pharmacology +10

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono et al. · Journal of Pharmacological Sciences · 2016 · 148 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo

Atsuo Tahara, Yuichi Tomura, Koh‐ichi Wada et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 140 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology · 2014 · 125 citations

Medicine, Pharmacology, Pharmacotherapy +17